Literature DB >> 9766266

Role of GnRH drive in the pathophysiology of polycystic ovary syndrome.

M P Leondires1, S L Berga.   

Abstract

Polycystic ovary syndrome may result from multiple mechanisms, but full expression of the PCO syndrome with hyperandrogenic anovulation depends upon sustained LH drive and relative FSH deficiency. We have described possible intrinsic and extrinsic factors capable of modifying the hypothalamic-pituitary-ovarian axis. Available evidence suggests the presence of an intrinsic alteration in GnRH-LH drive. The long-term natural history of HAA is variable and depends on several factors including obesity, aberrations in insulin action, intrinsic ovarian function, and end-organ responsiveness to androgens. Figure 1 presents a conceptualization of the pathogenesis of PCOS diagramming the multiple modulators of its expression. Long-term suppression of androgens when fertility is not desired should modify the full expression of the PCO syndrome. It is important to appreciate that therapy with oral contraceptive agents has few drawbacks and many immediate and potential long-term benefits for women with HAA. This therapy may be of greatest benefit when started in adolescence prior to the progression of obesity, hirsutism, and thecal-stromal hyperplasia. Women with HAA represent a large subgroup of patients who require individualization of their health care with sensitivity to issues surrounding anovulation, obesity, hirsutism, and infertility.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766266     DOI: 10.1007/BF03347331

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  76 in total

1.  Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameters.

Authors:  I M Chapman; G A Wittert; R J Norman
Journal:  Clin Endocrinol (Oxf)       Date:  1997-02       Impact factor: 3.478

Review 2.  Insulin resistance--mechanisms, syndromes, and implications.

Authors:  D E Moller; J S Flier
Journal:  N Engl J Med       Date:  1991-09-26       Impact factor: 91.245

Review 3.  Polycystic ovary syndrome: a changing perspective.

Authors:  S Franks
Journal:  Clin Endocrinol (Oxf)       Date:  1989-07       Impact factor: 3.478

Review 4.  Polycystic ovary syndrome.

Authors:  S Franks
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

5.  Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin.

Authors:  A H Balen; S L Tan; J MacDougall; H S Jacobs
Journal:  Hum Reprod       Date:  1993-06       Impact factor: 6.918

6.  Human female phenotypic development: role of fetal ovaries.

Authors:  A C Ammini; J Pandey; M Vijyaraghavan; U Sabherwal
Journal:  J Clin Endocrinol Metab       Date:  1994-08       Impact factor: 5.958

7.  Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia?

Authors:  J H Levin; E Carmina; R A Lobo
Journal:  Fertil Steril       Date:  1991-10       Impact factor: 7.329

Review 8.  Neuropeptide Y. A novel sympathetic stress hormone and more.

Authors:  Z Zukowska-Grojec
Journal:  Ann N Y Acad Sci       Date:  1995-12-29       Impact factor: 5.691

9.  Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes.

Authors:  J S Flier; R C Eastman; K L Minaker; D Matteson; J W Rowe
Journal:  Diabetes       Date:  1985-02       Impact factor: 9.461

10.  The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome.

Authors:  R A Wild; M J Bartholomew
Journal:  Am J Obstet Gynecol       Date:  1988-08       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.